



Media Releases » **Torrent Pharma records 19% growth in Revenues during Q1 12-13**

July 23rd, 2012

Ahmedabad-based Torrent Pharmaceuticals Limited, today released its financial results for the quarter ended 30th June, 2012. The Q1'12-13 revenues stood at Rs. 767 crores, up by 19% from Rs. 642 crores in the comparable quarter of last year.

During Q1, domestic formulation business recorded revenues of Rs. 279 crores, growing by 14%. International revenues grew by 33% to Rs. 422 crores. Operations in Brazil registered revenue growth of 26%. Revenues from the US operations recorded growth of 78% while business from Europe (other than Heumann), Russia & CIS and Rest of the World recorded a growth of 40%.

Operating profits (PBDIT) for the quarter stood at Rs. 156 crores showing a growth of 4%. Brazil base effect was the main factor leading to lower growth in operating profits. Net profit before Taxes for the quarter grew by 7% to Rs. 140 crores compared to Rs. 131 crores during the same period last year.

The total revenue expenditure on R&D was 4% of consolidated net sales and operating income.

About Torrent Pharma: Torrent Pharma, with an annual turnover of over Rs. 2,650 crores is the flagship company of the Torrent Group. With many of its products ranking among the Top 200 brands, Torrent continues to be at the forefront of the Indian pharmaceutical industry through research, innovation and breakthrough discoveries in the therapeutics areas of Diabetology, Cardiovascular, Central Nervous System, Gastro-Intestinal, Anti-infective, Pain management and Gynecology. Its Research Center employs over 640 scientists in the areas of drug discovery and development. Currently, Torrent has various discovery projects in pipeline. It has filed 450 patents for NCE's in all major markets worldwide, of which 211 patents have been granted so far. Torrent's manufacturing plant at Chhatral has a capacity to manufacture approx. 5,500 million Tablets, capsules and vials and 45,000 kgs of Bulk Drugs/API. The facility has already been approved by authorities from regulated markets like US, UK, Germany, Australia and South Africa. The manufacturing plant at Baddi has a capacity to manufacture 3,300 million tablets and 350 million capsules. The newly constructed manufacturing plant at Sikkim has a capacity to manufacture 3,900 million tablets per annum.